search
Back to results

The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy

Primary Purpose

Parkinson Disease, Dystonia

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Summit RC+S for Motor
8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Summit RC+S for Sleep
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease

Eligibility Criteria

21 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

Parkinson's Disease:

  1. Ability to give informed consent for the study
  2. Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria
  3. Patient has requested surgical intervention with deep brain stimulation for their disorder
  4. No MR abnormalities that suggest an alternative diagnosis or contraindicate surgery
  5. Absence of significant cognitive impairment (score of 20 or greater on the Montreal Cognitive Assessment (MoCA),
  6. Signed informed consent
  7. Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment.
  8. Age 21-75 (for STN patients, minimum age is 25)
  9. Diagnosis of idiopathic PD with duration of motor symptoms for 4 years or greater
  10. Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist, and has had stable doses of antiparkinsonian medications for 30 days prior to baseline assessment.
  11. UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia.

OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management

Dystonia:

  1. Ability to give informed consent for the study
  2. Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria
  3. Patient has requested surgical intervention with deep brain stimulation for their disorder
  4. No MR abnormalities that suggest an alternative diagnosis or contraindicate surgery
  5. Absence of significant cognitive impairment (score of 20 or greater on the Montreal Cognitive Assessment (MoCA)
  6. Signed informed consent
  7. Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment.
  8. Age 21-75
  9. Diagnosis of Isolated dystonia, which may be focal cervical, segmental craniocervical, or generalized forms.
  10. Stable doses of anti-dystonia medications (such as trihexyphenydil, Baclofen, or clonazepam) for at least 30 days prior to baseline assessment
  11. For dystonia patients with craniofacial and cervical involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms.

Exclusion Criteria

Parkinson's Disease:

  1. Coagulopathy, anticoagulant medications, uncontrolled hypertension, history of seizures, heart disease, or other medical conditions considered to place the patient at elevated risk for surgical complications
  2. Evidence of a psychogenic movement disorder: Motor symptoms that remit with suggestion or "while unobserved", symptoms that are inconsistent over time or incongruent with clinical condition, plus other manifestation such as "false" signs, multiple somatizations, or obvious psychiatric disturbance.
  3. Pregnancy: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.
  4. Significant untreated depression (BDI-II score >20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS)
  5. Any personality or mood symptoms that study personnel believe will interfere with study requirements.
  6. Subjects who require ECT, rTMS or diathermy
  7. Implanted stimulation systems such as; cochlear implant, pacemaker, defibrillator, neurostimulator or metallic implant
  8. Previous cranial surgery
  9. Drug or alcohol abuse
  10. Meets criteria for Parkinson's disease with mild cognitive impairment (PD-MCI). These criteria are: performance of more than two standard deviations below appropriate norms, for tests from two or more of these five cognitive domains: attention, executive function, language, memory, and visuospatial tests.

Dystonia:

  1. Coagulopathy, anticoagulant medications, uncontrolled hypertension, history of seizures, heart disease, or other medical conditions considered to place the patient at elevated risk for surgical complications
  2. Evidence of a psychogenic movement disorder: Motor symptoms that remit with suggestion or "while unobserved", symptoms that are inconsistent over time or incongruent with clinical condition, plus other manifestation such as "false" signs, multiple somatizations, or obvious psychiatric disturbance.
  3. Pregnancy: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure.
  4. Significant untreated depression (BDI-II score >20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS)
  5. Any personality or mood symptoms that study personnel believe will interfere with study requirements.
  6. Subjects who require ECT, rTMS or diathermy
  7. Implanted stimulation systems such as; cochlear implant, pacemaker, defibrillator, neurostimulator or metallic implant
  8. Previous cranial surgery
  9. Drug or alcohol abuse

Sites / Locations

  • University of California at San Francisco

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Parkinson's Disease STN Target

Parkinson's disease patients GP Target

Dystonia patients

Arm Description

Parkinson's disease patients implanted in STN

Parkinson's disease patients implanted in Globus Pallidus

Isolated dystonia patients

Outcomes

Primary Outcome Measures

Duration of 'on' stimulation time without dyskinesia from motor diaries in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Duration of 'on' stimulation time without dyskinesia in adaptive compared to standard open loop stimulation determined from the patients' motor diaries. The self-report motor diary is a validated method to capture this information. Every half-hour, patients indicate in this diary which of 4 categories (on, on with troubling dyskinesia, off, or asleep) best reflected their predominant symptoms for the prior 30 minutes. Patients will complete this diary for 3 consecutive days. The total time spent in the 'on' state without troubling dyskinesia will then be summed and averaged over 3 days for all three conditions (baseline, open-loop stimulation and closed-loop stimulation).
The Burke-Fahn-Marsden Dystonia Rating Scale-Movement aDBS testing compared to pre-operative baseline(Dystonia Patients)
This scales evaluates dystonia in nine body areas, including eyes, mouth, speech and swallowing, neck, trunk, and right and left arm and leg. The maximal total score is 120 - a higher score means worsening symptoms. Investigators will compare the dystonia symptoms and functional disability during adaptive stimulation compared to preoperative baseline.
Toronto Western Spasmodic Torticollis Rating Scale during aDBS testing compared to pre-operative baseline (Dystonia Patients)
This is a standardized scale to measure the severity, disability, and pain associated with cervical dystonia. The motor severity subscale consists of 10 items, with variable scaling and weighting. It also includes a disability scale with six items,and a pain scale with three items. The total score is the sum of each of the subscales. A higher score indicates greater disability.
Karolinska Sleepiness Scale
This is a standardized scale for measuring sleepiness
Psychomotor vigilance task (PVT)
This is a standardized behavioral task for measure alertness and attention
Positive and Negative Affect Schedule (PANAS-SF)
This is a standardized mood questionnaire

Secondary Outcome Measures

The Unified Parkinsons Disease Rating Scale (UPDRS) III scores off of medication in adaptive compared to standard open-loop stimulation. (Parkinson's disease patients)
The UPDRS III is a motor rating scale. Investigators will compare the severity motor symptoms while the patient is off of Parkinsoniae (UPDRS) III scores off of medication in adaptive compared to standard open-loop stimulation. (Parkinson's disease patients)n medications in conventional (open-loop) versus adaptive (closed-loop) DBS.
Schwab England scale in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
This scale estimates the abilities of individuals living with Parkinson's Disease relative to a completely independent situation. Investigators will use it to compare the abilities of daily living in subjects during the open-loop and adaptive stimulation trial.
Hoehn and Yahr Staging in the medication 'on' state in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
The Hoehn and Yahr scale are used to describe the progression of Parkinson's disease based upon the level of motor impairment. This scale only includes one score ranging from 1 to 5 where a higher score indicates a higher level of motor impairment. Investigators will compare the level of disease progression between the open-loop and adaptive stimulation conditions.
The patient' quality of life report (PDQ-39) in adaptive compared to standard open loop stimulation. The PDQ39 yields a score between 0 to 100, where a higher score indicates more health problems. (Parkinson's disease patients)
The PDQ 39 questionnaire has 39 questions to assess the patient's life quality including mobility, emotional state, and bodily comfort. Investigators will make a comparison of patients' life quality of life between open-loop and adaptive stimulation.
Patient's Global Impression of Change (PGIC) in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Patient Global Impression of Changes measures the self-reported level of overall improvement (motor and non-motor symptoms) in a patient on a 1-7 scale. A one indicates no change and a 7 is the greatest level of improvement.
Total Electric Energy Delivered (TEED) by the pulse generator in adaptive compared to standard open loop stimulation. (all patients)
Investigators will compare the total charge delivered by the pulse generator between open-loop and adaptive stimulation to determine if there is a potential energy savings.
Short form 36 Quality of Life measure (Dystonia Patients)
The SF-36 is a measure of self-reported health status which is scored on a 0-100 scale. The lower the score the more disability a patient experiences.
Patient Global Impression of Change (Dystonia Patients)
Patient Global Impression of Changes measures the self-reported level of overall improvement (motor and non-motor symptoms) in a patient on a 1-7 scale. A one indicates no change and a 7 is the greatest level of improvement.
Resting state EEG Recording
Resting state cortical power will be analyzed as a surrogate marker of alertness

Full Information

First Posted
June 14, 2018
Last Updated
January 15, 2023
Sponsor
University of California, San Francisco
search

1. Study Identification

Unique Protocol Identification Number
NCT03582891
Brief Title
The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy
Official Title
Closed Loop Deep Brain Stimulation in Parkinson's Disease and Dystonia (Activa RC+S)
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 1, 2018 (Actual)
Primary Completion Date
July 1, 2025 (Anticipated)
Study Completion Date
March 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Francisco

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is an exploratory pilot study to identify neural correlates of specific motor signs in Parkinson's disease (PD) and dystonia, using a novel totally implanted neural interface that senses brain activity as well as delivering therapeutic stimulation. Parkinson's disease and isolated dystonia patients will be implanted unilaterally or bilaterally with a totally internalized bidirectional neural interface, Medtronic Summit RC+S. This study includes three populations: ten PD patients undergoing deep brain stimulation in the subthalamic nucleus (STN), ten PD patients with a globus pallidus (GPi) target and five dystonia patients. All groups will test a variety of strategies for feedback-controlled deep brain stimulation, and all patients will undergo a blinded, small pilot clinical trial of closed-loop stimulation for thirty days.
Detailed Description
In this project investigators will develop adaptive DBS algorithms based on cortical and subcortical signals using the RC+S. This bidirectional neural interface is rechargeable (for up to 9 years of use), and is capable of delivering therapeutic open-loop stimulation or closed-loop stimulation. Its sensing capability includes four simultaneous time series channels at up to 1000 Hz sampling rate. In addition the device can stream time series data, and calculate and stream spectral power within a preset bandwidth. Twenty patients with idiopathic PD and motor fluctuations, or medically intractable tremor, will be implanted with unilateral or bilateral RC+S devices, each connected to a standard quadripolar DBS lead implanted in STN or globus pallidus, and to a 4-contact paddle type electrode placed subdurally over sensorimotor cortex. The basal ganglia lead will be used for both stimulation and LFP recordings, while the cortical lead will be used only for recording ECoG potentials, not for stimulation. Patients with motor fluctuations cycle between a hypokinetic state (too little movement) and a hyperkinetic state (excessive movement). During open-loop DBS, brain state continues to fluctuate between these states and stimulation may induce dyskinesia or inadequately relieve akinesia. With the goal of maintaining motor function within a normal range away from these two extremes, investigators will develop and test stimulation algorithms that utilize putative markers of both kinetic states. Investigators will also study neural signals of sleep and test stimulation to support specific sleep stages. The basic strategy is to automatically adjust stimulation parameters until the physiological signature of abnormal function is minimized. First, investigators will prototype adaptive stimulation paradigms and briefly (2 hours) test them in clinic, using a "distributed" configuration (streaming to a computer). Then, investigators will embed these algorithms in RC+S to test chronic and fully closed-loop DBS in a small double-blinded clinical trial. Investigators will pay careful attention to the possibility of progressive reduction in stimulation currents over the course of the study, which could support the hypothesis that "adaptive stimulation" might make the brain progressively less dependent on the device. In quantifying DBS amplitude and comparing open loop with adaptive stimulation, an important parameter is the total electrical energy delivered (TEED). TEED is calculated by the following equation as suggested by Koss and colleagues (TEED1sec = ((voltage2 x frequency x pulsewidth)/impedance) x 1sec). This can be used as measure of the energy saved when stimulation is delivered in closed-loop mode relative to empiric open-loop stimulation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease, Dystonia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Investigators will run a pilot clinical trial in which individualized classifier/control strategies for each hemisphere in each subject will be embedded within the RC+S for a total of one month (x4 one week blocks) of feedback-controlled stimulation will be compared with a total of one month of empirically optimized open-loop stimulation, (x4 one week blocks), administered in randomized order with adaptive stimulation. During these 1-month trials, patients and neurologists will be blinded to the state of the stimulator.
Masking
ParticipantOutcomes Assessor
Masking Description
Subjects with Parkinson's disease who are being implanted in the STN will be blinded to the type of stimulation received (open-loop or closed-loop phases) during the chronic adaptive DBS testing phase (period 4) at home. Each of these subjects will have blinded open-loop or closed-loop stimulation for a total of one month. The use of objective measures of motor function such as wearable devices, in addition physician administered rating scales, is a strategy to reduce observer bias. For physician administered scales, all exams will be videotaped so that these can be reviewed by a blinded neurologist evaluator.
Allocation
Randomized
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Parkinson's Disease STN Target
Arm Type
Other
Arm Description
Parkinson's disease patients implanted in STN
Arm Title
Parkinson's disease patients GP Target
Arm Type
Other
Arm Description
Parkinson's disease patients implanted in Globus Pallidus
Arm Title
Dystonia patients
Arm Type
Other
Arm Description
Isolated dystonia patients
Intervention Type
Device
Intervention Name(s)
Summit RC+S for Motor
Intervention Description
Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
Intervention Type
Diagnostic Test
Intervention Name(s)
8-week pilot trial of Closed-loop vs. Open-loop Stimulation
Intervention Description
These patients will participate in an 8 week clinical trial of open loop versus adaptive mode (4 weeks for each mode (interleaved), with the order counterbalanced across subjects ).
Intervention Type
Device
Intervention Name(s)
Summit RC+S for Sleep
Other Intervention Name(s)
Sleep
Intervention Description
Using the RC+S pulse generator, investigators will measure cortical biomarkers of sleep stages in Parkinson's patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
Primary Outcome Measure Information:
Title
Duration of 'on' stimulation time without dyskinesia from motor diaries in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Description
Duration of 'on' stimulation time without dyskinesia in adaptive compared to standard open loop stimulation determined from the patients' motor diaries. The self-report motor diary is a validated method to capture this information. Every half-hour, patients indicate in this diary which of 4 categories (on, on with troubling dyskinesia, off, or asleep) best reflected their predominant symptoms for the prior 30 minutes. Patients will complete this diary for 3 consecutive days. The total time spent in the 'on' state without troubling dyskinesia will then be summed and averaged over 3 days for all three conditions (baseline, open-loop stimulation and closed-loop stimulation).
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
The Burke-Fahn-Marsden Dystonia Rating Scale-Movement aDBS testing compared to pre-operative baseline(Dystonia Patients)
Description
This scales evaluates dystonia in nine body areas, including eyes, mouth, speech and swallowing, neck, trunk, and right and left arm and leg. The maximal total score is 120 - a higher score means worsening symptoms. Investigators will compare the dystonia symptoms and functional disability during adaptive stimulation compared to preoperative baseline.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Toronto Western Spasmodic Torticollis Rating Scale during aDBS testing compared to pre-operative baseline (Dystonia Patients)
Description
This is a standardized scale to measure the severity, disability, and pain associated with cervical dystonia. The motor severity subscale consists of 10 items, with variable scaling and weighting. It also includes a disability scale with six items,and a pain scale with three items. The total score is the sum of each of the subscales. A higher score indicates greater disability.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Karolinska Sleepiness Scale
Description
This is a standardized scale for measuring sleepiness
Time Frame
Through study completion, up to 4 years
Title
Psychomotor vigilance task (PVT)
Description
This is a standardized behavioral task for measure alertness and attention
Time Frame
Through study completion, up to 4 years
Title
Positive and Negative Affect Schedule (PANAS-SF)
Description
This is a standardized mood questionnaire
Time Frame
Through study completion, up to 4 years
Secondary Outcome Measure Information:
Title
The Unified Parkinsons Disease Rating Scale (UPDRS) III scores off of medication in adaptive compared to standard open-loop stimulation. (Parkinson's disease patients)
Description
The UPDRS III is a motor rating scale. Investigators will compare the severity motor symptoms while the patient is off of Parkinsoniae (UPDRS) III scores off of medication in adaptive compared to standard open-loop stimulation. (Parkinson's disease patients)n medications in conventional (open-loop) versus adaptive (closed-loop) DBS.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Schwab England scale in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Description
This scale estimates the abilities of individuals living with Parkinson's Disease relative to a completely independent situation. Investigators will use it to compare the abilities of daily living in subjects during the open-loop and adaptive stimulation trial.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Hoehn and Yahr Staging in the medication 'on' state in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Description
The Hoehn and Yahr scale are used to describe the progression of Parkinson's disease based upon the level of motor impairment. This scale only includes one score ranging from 1 to 5 where a higher score indicates a higher level of motor impairment. Investigators will compare the level of disease progression between the open-loop and adaptive stimulation conditions.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
The patient' quality of life report (PDQ-39) in adaptive compared to standard open loop stimulation. The PDQ39 yields a score between 0 to 100, where a higher score indicates more health problems. (Parkinson's disease patients)
Description
The PDQ 39 questionnaire has 39 questions to assess the patient's life quality including mobility, emotional state, and bodily comfort. Investigators will make a comparison of patients' life quality of life between open-loop and adaptive stimulation.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Patient's Global Impression of Change (PGIC) in adaptive compared to standard open loop stimulation. (Parkinson's disease patients)
Description
Patient Global Impression of Changes measures the self-reported level of overall improvement (motor and non-motor symptoms) in a patient on a 1-7 scale. A one indicates no change and a 7 is the greatest level of improvement.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Total Electric Energy Delivered (TEED) by the pulse generator in adaptive compared to standard open loop stimulation. (all patients)
Description
Investigators will compare the total charge delivered by the pulse generator between open-loop and adaptive stimulation to determine if there is a potential energy savings.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Short form 36 Quality of Life measure (Dystonia Patients)
Description
The SF-36 is a measure of self-reported health status which is scored on a 0-100 scale. The lower the score the more disability a patient experiences.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Patient Global Impression of Change (Dystonia Patients)
Description
Patient Global Impression of Changes measures the self-reported level of overall improvement (motor and non-motor symptoms) in a patient on a 1-7 scale. A one indicates no change and a 7 is the greatest level of improvement.
Time Frame
Comparison will use data from the testing of open and closed-loop stimulation during chronic adaptive DBS testing at home.
Title
Resting state EEG Recording
Description
Resting state cortical power will be analyzed as a surrogate marker of alertness
Time Frame
Through study completion, up to 4 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Parkinson's Disease: Ability to give informed consent for the study Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria Patient has requested surgical intervention with deep brain stimulation for their disorder No MR abnormalities that suggest an alternative diagnosis or contraindicate surgery Absence of significant cognitive impairment (score of 20 or greater on the Montreal Cognitive Assessment (MoCA), Signed informed consent Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment. Age 21-75 (for STN patients, minimum age is 25) Diagnosis of idiopathic PD with duration of motor symptoms for 4 years or greater Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist, and has had stable doses of antiparkinsonian medications for 30 days prior to baseline assessment. UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management Dystonia: Ability to give informed consent for the study Movement disorder symptoms that are sufficiently severe, in spite of best medical therapy, to warrant surgical implantation of deep brain stimulators according to standard clinical criteria Patient has requested surgical intervention with deep brain stimulation for their disorder No MR abnormalities that suggest an alternative diagnosis or contraindicate surgery Absence of significant cognitive impairment (score of 20 or greater on the Montreal Cognitive Assessment (MoCA) Signed informed consent Ability to comply with study follow-up visits for brain recording, testing of adaptive stimulation, and clinical assessment. Age 21-75 Diagnosis of Isolated dystonia, which may be focal cervical, segmental craniocervical, or generalized forms. Stable doses of anti-dystonia medications (such as trihexyphenydil, Baclofen, or clonazepam) for at least 30 days prior to baseline assessment For dystonia patients with craniofacial and cervical involvement, prior treatment with botulinum toxin with failure to adequately control dystonia symptoms. Exclusion Criteria Parkinson's Disease: Coagulopathy, anticoagulant medications, uncontrolled hypertension, history of seizures, heart disease, or other medical conditions considered to place the patient at elevated risk for surgical complications Evidence of a psychogenic movement disorder: Motor symptoms that remit with suggestion or "while unobserved", symptoms that are inconsistent over time or incongruent with clinical condition, plus other manifestation such as "false" signs, multiple somatizations, or obvious psychiatric disturbance. Pregnancy: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure. Significant untreated depression (BDI-II score >20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS) Any personality or mood symptoms that study personnel believe will interfere with study requirements. Subjects who require ECT, rTMS or diathermy Implanted stimulation systems such as; cochlear implant, pacemaker, defibrillator, neurostimulator or metallic implant Previous cranial surgery Drug or alcohol abuse Meets criteria for Parkinson's disease with mild cognitive impairment (PD-MCI). These criteria are: performance of more than two standard deviations below appropriate norms, for tests from two or more of these five cognitive domains: attention, executive function, language, memory, and visuospatial tests. Dystonia: Coagulopathy, anticoagulant medications, uncontrolled hypertension, history of seizures, heart disease, or other medical conditions considered to place the patient at elevated risk for surgical complications Evidence of a psychogenic movement disorder: Motor symptoms that remit with suggestion or "while unobserved", symptoms that are inconsistent over time or incongruent with clinical condition, plus other manifestation such as "false" signs, multiple somatizations, or obvious psychiatric disturbance. Pregnancy: all women of child bearing potential will have a negative urine pregnancy test prior to undergoing their surgical procedure. Significant untreated depression (BDI-II score >20) History of suicidal attempt or active suicidal ideation (Yes to #2-5 on C-SSRS) Any personality or mood symptoms that study personnel believe will interfere with study requirements. Subjects who require ECT, rTMS or diathermy Implanted stimulation systems such as; cochlear implant, pacemaker, defibrillator, neurostimulator or metallic implant Previous cranial surgery Drug or alcohol abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip A Starr, MD/PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California at San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94115
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
33152715
Citation
Powell MP, Anso J, Gilron R, Provenza NR, Allawala AB, Sliva DD, Bijanki KR, Oswalt D, Adkinson J, Pouratian N, Sheth SA, Goodman WK, Jones SR, Starr PA, Borton DA. NeuroDAC: an open-source arbitrary biosignal waveform generator. J Neural Eng. 2021 Feb 5;18(1):10.1088/1741-2552/abc7f0. doi: 10.1088/1741-2552/abc7f0.
Results Reference
derived

Learn more about this trial

The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy

We'll reach out to this number within 24 hrs